



World Health
Organization

REGIONAL OFFICE FOR

South-East Asia



OFFICE ADDRESS:

PERMANENT: WORLD HEALTH HOUSE, INDRAPRASTHA ESTATE, MAHATMA GANDHI ROAD, NEW DELHI-110 002, INDIA. WWW.SEARO.WHO.INT

TEMPORARY: METROPOLITAN HOTEL OFFICE BLOCK, BANGLA SAHIB ROAD, GOLE MARKET, SECTOR 4, NEW DELHI-110 001, INDIA
ANNEX – RED FORT CAPITAL PARSVNATH TOWER 1, BHAI VIR SINGH MARG, GOLE MARKET, SECTOR 4, NEW DELHI-110 001, INDIA
TEL: 91-11-4304 0200 /0161, FAX: 91-11-2336 8355

In reply please refer to: M3/15/1

Dr Niranana Mahantashetti
Director
Women's and Children's Health Research Unit
Jawaharlal Nehru Medical College, KLE
Academy of Higher Education and Research,
Belagavi (JNMC Research Unit)
Karnataka 590010, India

16 September 2019

Dear Dr Mahantashetti

Subject: Designation of Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi (JNMC Research Unit) as a WHO Collaborating Centre for Research in Maternal and Perinatal Health (WHO-CC IND 156)

I am pleased to inform you that the World Health Organization has designated the Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi (JNMC Research Unit) as a WHO Collaborating Centre for Research in Maternal and Perinatal Health (WHO-CC IND 156).

As previously agreed, Dr Shivaprasad Goudar will act as Head of the Centre. Should there be any change in the future, I would be grateful if you would inform WHO without delay.

The agreed terms of reference and workplan of the Centre are attached. We wish to emphasize that institutions designated as WHO Collaborating Centres are expected to implement the agreed workplan in a timely manner and to the highest possible standard of quality. Any issue that may affect the implementation of the agreed workplan should be brought to the attention of the WHO responsible officer, Dr Mariana Widmer, Technical Officer, HQ/MPA Maternal Perinatal Health, Prevent Unsafe Abortion Tel:+41 22 791 4323, Email: widmerm@who.int

For information on administrative matters, please visit the WHO website <http://www.who.int/collaboratingcentres/information/en/>.

We wish to also emphasize that institutions designated as WHO Collaborating Centres must also comply with the attached terms and conditions for WHO collaborating centres. We wish to draw your particular attention to the fact that the WHO name and emblem may only be used by a WHO Collaborating Centre as described in those terms and conditions.

Cont'd...2/-

- cc: The Secretary, Ministry of Health and Family Welfare, Government of India,
Nirman Bhawan, New Delhi
- cc: The Joint Secretary (IH Division), Ministry of Health and Family Welfare,
Government of India, Nirman Bhawan, New Delhi
- cc and through: The WHO Representative to India, Nirman Bhawan, New Delhi

4/10/2019

Dr Niranana Mahantashetti
Director
Women's and Children's Health Research Unit
Jawaharlal Nehru Medical Collage,
KLE Academy of Higher Education and Research,
Belagavi (JNMC Research Unit)
Karnataka 590010

M3/15/1

16 September 2019

Finally, please note that institutions designated as WHO Collaborating Centres must complete a short online progress report form once a year. On the anniversary of the designation date, details will be sent to the email address of the Head of the Centre specified in the designation form.

The designation of your institution as a WHO Collaborating Centre will be effective for a period of 4 years from **17 September 2019**, and will automatically end on **17 September 2023**, unless redesignation has been approved by WHO before that date. During the period of designation, either party may revoke the designation at any time by giving three months advance notice in writing.

I look forward to our successful collaboration.

Yours sincerely,


Dr Poonam Khetrpal Singh
Regional Director

Encl: As stated



Collaborating Centres DESIGNATION FORM

The designation form consists of three parts:

Part I - Institutional Profile

Part II - Terms of Reference (TOR)

Part III - Workplan

This designation form below, together with the Terms and conditions for WHO collaborating centres will serve as the agreement between the proposed institution and WHO if the designation as WHO collaborating centre is approved by WHO. Completion and submission of the designation form, however, does not guarantee that the designation will be approved.

Folder eCC_00018907 is in stage Notification Letter

Name of the University, Hospital, Research Institute, Academy or Ministry	
Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi (JNMC Research Unit)	
Name of the Division, Department, Unit, Section or Area	
Women's and Children's Health Research Unit	
City	CC Reference Number
Belagavi	IND-156
Title	
WHO collaborating centre for research in maternal and perinatal health	

Part I - Institutional Profile	
<p>The status of WHO CC is granted to an administrative unit of an institution (i.e. department, division or unit) and not to the institution as a whole in the vast majority of cases. For example, WHO CC status is granted to the Department of Microbiology of the University of ABC and not to the university itself. A WHO CC is not a legal entity. The legal entity is the proposed institution, i.e. the ministry, academy, university, established research institute or hospital, of a part thereof.</p> <p>In the section entitled "sources of funding" some questions refer to the proposed terms of reference and activities included in the workplan of this proposal. Therefore please limit your responses to what is relevant in relation to the proposed terms of reference and activities included in the workplan.</p> <p>However, when a question refers to the "proposed institution", please provide information on the legal entity as a whole (for example the University of ABC).</p>	
Address of the proposed institution	
1.1 Street and number	JNMC Campus, Nehru Nagar
1.2 City	Belagavi
1.3 State/Region/Canton/Province	Karnataka
1.4 Postal Code	590010
1.5 Country	IND
1.6 WHO Region	SEARO



Collaborating Centres DESIGNATION FORM

1.7 Phone +91 831 247 4200
 1.8 Fax +918312472891
 1.9 Web site <http://kledeemeduniversity.edu.in/>

If you would like your institution to receive important news and other communications from WHO (unrelated to the work as a WHO CC) such as launching of new WHO campaigns, new WHO publications, etc, please indicate an email address.

Staff of the proposed institution

1.10 Name of the director of the institution as a whole

Dr Niranjana Mahantashetti

1.11 - Name and email of the proposed heads of the WHO collaborating centre (Please note this information will be listed in the public database)

Salutation	First Name	Last Name	Email Address
Dr	Shivaprasad	Goudar	sgoudar@jnmc.edu
Salutation	First Name	Last Name	Email Address

1.12 Please list the names of professional who will work on the proposed terms of reference or activities of the workplan together with their professional qualifications (e.g. Dr John Smith MPH). Please do not include full resumes or biographies.

- Dr Avinash Kavi MD
- Dr Yogesh Kumar S MD
- Dr Sunil S Vernekar MD
- Dr Yeshita V Pujar MD
- Dr Manjunath S Somannavar MD
- Dr Sangappa M Dhaded MD DM
- Dr Shivaprasad S Goudar MD

Sources of funding

NOTE: Private-sector entities in this form refer to three categories: (i) business associations representing commercial enterprises, (ii) entities that are not at "arms' length" from their commercial sponsors, and (iii) partially or fully state-owned commercial enterprises that act like private-sector entities.

An entity that is "at arms' length" from another entity should meet the following three conditions: (i) to be financially and organizationally independent from the other entity, (ii) not to take instructions from the other entity, and (iii) not to be influenced or not reasonably perceived to be influenced in its decisions, activities, mandate and work by the other entity.

1.13 During the last two years, what percentage of the funding of the proposed institution was core funding? Core funding refers to funding that is received regularly from secure sources, as opposed to ad-hoc contributions.

over 75% regular (core) funding

1.14 Please provide a complete list of donors that provide funding for the proposed institution, such as private-sector organizations, philanthropic foundations, nongovernmental organizations, governments, inter-governmental organizations and members of the public. Please include the full names of all donors, but not the amount donated.



Collaborating Centres DESIGNATION FORM

KLE Academy of Higher Education and Research- Not Applicable- >75% of the core funding is through tuition fees from students of the University.

JNMC Women's and Children's Health Research Unit- NICHD Eunice Shriver Kennedy Global Network for Women's and Children's Health Research (currently in the fourth cycle of funding), World Health Organization, the National Institute of Child Health and Human Development, the American Academy of Pediatrics, the Thrasher Research Fund, UK Medical Research Council – Department of Bio-technology, Govt. of India Newton-Bhabha Fund, and the Bill & Melinda Gates Foundation.

With reference to the proposed terms of reference and activities included in the workplan of this proposal- Source of funding is included in the work plan document.

1.15 Tobacco/arms-related disclosure statement .

Under the WHO Framework of Engagement with non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry.

Moreover, WHO does not engage with the arms industry.

For the purposes of this statement: tobacco industry refers to any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such an entity; and arms industry refers to any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such an entity.

To determine whether the proposed institution conforms to this rule, please answer the following questions:

- Is the proposed institution, or was the proposed institution over the last four years, part of the tobacco or arms industries (as defined above)?
• Is the proposed institution, or has the proposed institution over the last four years, engaged in activities that support the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.
• Does the proposed institution currently, or did the proposed institution over the last four years, have any other association or relationship with the tobacco industry (as defined above)? This includes in particular investment interests (other than general mutual funds or similar arrangements whereby the institution has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.
• Does the proposed institution have any formal association, affiliation or links with private-sector entities and other non-State actors whose policies or activities negatively affect human health and are not in line with WHO's policies, norms and standards, in particular those related to noncommunicable diseases and their determinants?

The answer is yes to at least one of the questions above. Please provide details []

By selecting this choice I confirm that the answer to all the questions above is no [x]

[If yes] Please provide details (i.e. the names of entities, their activities, level of funding).

1.16 Is there any prospect that the proposed terms of reference or activities of the workplan will be funded by one or more private-sector entities that have, or may be perceived as having, a direct or indirect commercial interest in those proposed terms of reference or activities of the workplan?

Yes [] No [x]

[If yes] Please provide the names of these entities, their business activities and the level of funding.

1.17 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, performed as part of or related to work (research or other) commissioned by private-sector entities?

Yes [] No [x]

[If yes] Please provide the names of these entities, their business activities and the level of funding.



1.18 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, funded directly or indirectly by unspecified funds from one or more private-sector entities?

Yes No

[if yes] Please provide the names of these entities, their business activities, level of funding, for what such funding is being, or will be, used and whether the implementation of the proposed terms of reference and activities of the workplan is dependent on the support of one or more of these private sector entities.

1.19 Are the salaries of staff who will work on the proposed terms of reference or activities of the workplan or their posts funded by one or more private sector entities, were they ever funded in this way in the past or could they receive such funding in future?

Yes No

[if yes] Please provide the names of these entities, their business activities, level of funding, for which staff or what posts such funding is being, or will be, used, and the functions of such staff and/or posts.

1.20 Did over the last three years, does currently, or is there a prospect that, any specific staff who will work on the proposed terms of reference or activities of the workplan (including the proposed head(s) of the WHO collaborating centre), have any other interactions, affiliations or relations with, or any other personal, professional, financial or business interests in, one or more private sector entities that could give rise to a real or perceived conflict of interest or reputational risk?

Such risks may exist

- (i) if the private sector entity has a direct or indirect commercial interest in all or part of the proposed terms of reference or activities of the workplan, or may be perceived as having such interest;
- (ii) if the business activities of the entity engage with the tobacco industry and /or arms industry; or non-State actors that work to further the interests of the tobacco industry ; or
- (iii) if the private sector entity has a vested interests in exerting influence on the proposed terms of reference or activities of the workplan and/or their outcome or may be seen as having such interest.

Interactions, affiliations, relations with, or other personal, professional, financial or business interests include, but are not necessarily limited to, collaborative projects or initiatives, employment, consultancy, investment interests (e.g. stocks, bonds, stock options, other securities, but not mutual funds, pension funds or similar investments that are broadly diversified), commercial business interests (e.g., proprietorships, partnerships, joint ventures), patents, trademarks, or copyrights (including pending applications), proprietary know-how in a substance, technology or process.

Yes No

[if yes] Please provide details.

Institutional characteristics

1.21 What type of entity is the proposed institution?

Private

Please provide details



Collaborating Centres DESIGNATION FORM

The K.L.E. Academy of Higher Education & Research was established on 13th April, 2006 as per the Ministry of Human Resource Development, Government of India, Notification No.F.9-19/2000-U-R(A) dated 13th April, 2006, under the recommendation of University Grants Commission.

Vision: " To be an outstanding university of excellence ever in pursuit of newer horizons- To build self reliant global citizens through assured quality educational Programmes".

Mission:

- To promote sustainable development of Higher Education consistent with statutory and regulatory requirements.
- To plan and continuously provide necessary infrastructure, learning resources required for Quality education and innovations.
- To stimulate, to extend the frontiers of knowledge, through Faculty Development and Continuing Education Programmes.
- To make research a significant activity involving Staff, Students and Society.
- To promote Industry / Organization, Interaction/Collaborations with Regional National / International bodies.
- To establish healthy systems for communication among all stake holders for vision oriented growth.
- To fulfill the National Obligation through Rural Health Missions.

The KLE Society, Sponsoring society of KAHER a private trust was established in the year 1916 and has been serving thousands of people in the field of education for nearly 10 decades! Presently, KLE Society manages a staggering 250 institutions including schools, colleges, technical institutions, research centers and Business schools.

University

By ticking this box you confirm that the entity you represent is a nonprofit entity.

1.22 Please attach a current organizational chart (1 page) of the institution, including its administrative units such as divisions, departments, sections or areas (whichever structure applies), indicating the one proposed as WHO collaborating centre.

Organisation Chart_KAHER.pdf

1.23 Please attach the constitutive documents of the institution you represent e.g. constitution, registration document, by-laws or similar.

MOA and Other Documents_KAHER.pdf

1.24 Number of years the institution is in operation.

more than 10 years

1.25 Please list major facilities and any specialized equipment available to the proposed institution (e.g. laboratories, training facilities, documentation centre), if applicable. Please do not list general office space or standard office equipment.

Clinical Skill laboratory (with Simulation, Mannequins and models)

Meeting rooms and Conference halls (40 and 100 seating capacity) in a dedicated building of about 9000 square feet

25 MPBS Internet leased line with fibre optic backbone and WIFI network

Server for data storage with and Data Management System facilities.

Facilities for scanning, photocopy, cold storage, Data Archival, Dining area

Basic Science Research Centre (Laboratory)

1.26 Does the proposed institution currently establish a smoke-free environment across its premises, which can be illustrated either through a documented institutional/departamental policy or through the existence of national/local smoke-free legislation? The smoke-free environment must apply to all indoor workplaces and public places of the institution's premises, and must entail a complete ban of smoking indoors and no areas designated for smoking.

Yes



Collaborating Centres DESIGNATION FORM

- I understand that information on my entity and its engagements with WHO that are categorized as public domain will be published in the WHO Register.
- The proposed institution agrees with the following Terms and conditions for WHO collaborating centres.

Part II - Terms of Reference (TOR)

Please include the proposed terms of reference for the future collaboration between the proposed institution and WHO, as discussed prior to completing this form. In most cases, 1-3 TOR will be sufficient to provide a high-level framework of the future collaboration. For redesignations, the current terms of reference is automatically prefilled but can be revised as appropriate.

For detailed instructions on how to fill in this section please click on the link provided at the top of the form.

- TOR 1** In alignment with WHO goals, to provide capacity building through Research Methodology Workshops at country level.
- TOR 2** To participate in collaborative research in the area of Maternal and Newborn Health developed under WHO's leadership.
- TOR 3** As agreed with WHO, disseminate and scale up evidence based interventions in the area of Maternal and Newborn Health.



Collaborating Centres DESIGNATION FORM

Part III - Workplan		
Activity ID 27838	Activity title Link to TOR Name(s) of responsible staff at the institution Type of activity Why WHO is asking for this activity and how WHO will use the deliverables? What concrete actions will be taken by the designated institution? Be specific.	<p>Capacity building in alignment with WHO goals, TOR1</p> <p>Dr Avinash Kavi, Dr Yogesh Kumar S, Dr M S Somannavar, Dr S M Dhaded, Dr S S Goudar.</p> <p>Training and education</p> <p>As part of WHO and HRP mandate, research projects include capacity building activities through which investigators receive training on research methodology. By doing this WHO/HRP ensures to have a large network of investigators capable of participating in any of the WHO research projects.</p> <p>In collaboration with WHO, the designated institution will develop the training curriculum for the research methodology (qualitative and quantitative) and statistics workshops, will customize it according to the participants needs, and will conduct it among mid-level faculty staff from India. Upon successful implementation of the workshops in India, the designated institution will evaluate the possibility of replicating the courses in Nepal and Bangladesh.</p> <p>Mid-level faculty staff includes Assistant and Associate Professors of various specialities, as well as Research Scholars working in Medical Colleges and Research Institutions respectively in the North Karnataka region with special focus on reproductive, maternal and newborn health.</p> <p>The training programme will focus on the different study designs used in research, on statistical methods for sample size calculation and for analysis of the research outcomes, and on quality control procedures during the implementation of the research project. At the end of the workshops, participants will be able to write full grant proposals and scientific manuscripts.</p> <p>Workshops will be of 5 days to 2 weeks duration. Each activity will accommodate a maximum of 20 participants.</p> <p>Any potential training to be delivered will not be of a qualifying nature (Masters, PhD, etc.) and the WHO name and logo will not be used on any document or certificate of participation or training.</p> <p>Faculty from Women's and Children's Health Research Unit of KLE Academy of Higher Education and Research's J N Medical College will conduct these workshops. Additional support will be sought from the members of</p>



Collaborating Centres DESIGNATION FORM

	Department of Medical Education J N Medical College Belagavi.
What will be WHO's role in this activity?	WHO will collaborate with the designated institution in defining the training programme and in selecting the participants. WHO will confirm the selection of participants for the training and will approve the final programme. In addition, WHO staff will provide technical guidance for and during the workshops.
Expected deliverables	Two workshops conducted. Capacity of participants on research methodology increased.
Intellectual property rights	IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions
WHO Deliverable Code	14.1.1.H3
Name(s) of funding sources	The cost of conducting these activities will be met from: 1. Indian Council of Medical Research, Fogarty International Centre and Bill & Melinda Gates Foundation 2. KLE Academy Higher Education and Research, Belagavi
Activity timeframe	Every year one workshop on grant writing for duration of 2 weeks and one workshop on manuscript writing for 1 week duration will be conducted.
This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.	



Collaborating Centres
DESIGNATION FORM

<p>Activity ID 27839</p>	<p>Activity title With the guidance and leadership form WHO, to conduct secondary analysis for CHAMPION Trial</p> <p>Link to TOR TOR2</p> <p>Name(s) of responsible staff at the institution Dr S S Vernekar, Dr Yeshita Pujar, Dr M S Somannavar, Dr S S Goudar,</p> <p>Type of activity Research</p> <p>Why WHO is asking for this activity and how WHO will use the deliverables? The CHAMPION trial database is a big and rich database which could answer lots of interesting questions related to the postpartum haemorrhage problematic. WHO/HRP does not have the capacity to run these analyses in a timely manner. Results of this analysis will help WHO understand the socio-economic aspects of the PPH problematic in one of the countries where the burden of this maternal complication is high.</p> <p>What concrete actions will be taken by the designated institution? Be specific. With WHO guidance, the designated institution will develop the protocol for the analysis proposed, run the proposed statistical analyses and prepare a report with the results.</p> <p>What will be WHO's role in this activity? WHO will guide the process for preparing the proposal, will guide the data analysis process, and will lead the discussion on the findings.</p> <p>Expected deliverables Publication on the Effectiveness of Heat stable Carbetocin compared to Oxytocin in women delivering at public and private sector hospitals of India.</p> <p>Intellectual property rights IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p>WHO Deliverable Code 3.1.5.H1</p> <p>Name(s) of funding sources Jawaharlal Nehru Medical College Women's and Children's Health Research Unit , Belgaum</p> <p>Activity timeframe December 2018: Secondary analyses to be completed. January 2019: Drafts of the publications for review. February 2019: Submission for publication</p> <p>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</p>
<p>Activity ID 27840</p>	<p>Activity title Knowledge Translation on Maternal and Perinatal Health Research Projects</p> <p>Link to TOR TOR3 Dr Yogesh Kumar S, Dr M S Somannavar, Dr S S Goudar, Dr.Yeshita Pujar, Dr.Sunil</p>



Collaborating Centres DESIGNATION FORM

<p>Name(s) of responsible staff at the institution</p>	<p>Vernekar</p>
<p>Type of activity</p>	<p>Information dissemination</p>
<p>Why WHO is asking for this activity and how WHO will use the deliverables?</p>	<p>The dissemination of the CHAMPION trial's results is very important for the uptake of the WHO postpartum haemorrhage recommendations by the country and it is part of the WHO/HRP agenda. India is one of the LMIC countries where the burden of postpartum haemorrhage is high and therefore, the need to implement the results of the CHAMPION trial is a priority for WHO. By requesting an Indian institute to disseminate the results in India, WHO is increasing the chances that the results of the research will be widely applied.</p>
<p>What concrete actions will be taken by the designated institution? Be specific.</p>	<p>Following WHO guidance and to raise awareness on how to prevent postpartum haemorrhage, the institution will present the results of CHAMPION Trial at All India Congress of Obstetrics & Gynaecology (AICOG) and at the congress organized by the Federation of Obstetrics & Gynaecological Societies of India (FOGSI). The designated institution will also present the results of the trial in Nepal, at the Reproductive Health Supply Coalition Caucus. In addition, with WHO leadership, the institution will implement a demonstration project to identify barriers and facilitators for the eventual national roll-out of the heat-stable carbetocin use in the area of postpartum haemorrhage.</p>
<p>What will be WHO's role in this activity?</p>	<p>WHO will prepare the presentation that will be used by the institution at different conferences, and will discuss it with the institution to ensure alignment on the message that has to be given to the audience. In regard to the demonstration project, WHO will work jointly with the institution in defining the project and the process for a successful implementation.</p>
<p>Expected deliverables</p>	<ol style="list-style-type: none"> 1. 3 abstracts for dissemination meetings in India and in Nepal. 2. Use of heat-stable carbetocin for postpartum haemorrhage prevention implemented at district level of the 6 Indian provinces that participated in the CHAMPION trial.
<p>Intellectual property rights</p>	<p>IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p>
<p>WHO Deliverable Code</p>	<p>3.1.1.R4</p>
<p>Name(s) of funding sources</p>	<p>Jawaharlal Nehru Medical College Women's and Children's Health Research Unit</p>



World Health
Organization

Collaborating Centres DESIGNATION FORM

Activity timeframe

December 2018 -March 2019: Dissemination meetings
April 2019: demonstration project proposal written
June 2019: Stakeholder meetings
August 2019: Training
October 2019-February 2020: Scale up

This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.